国药一致(000028.SZ)公告称，2025年上半年实现营业收入367.97亿元，同比下降2.62%；归属于上市公 司股东的净利润6.66亿元，同比下降10.43%。 ...

[Sinopharm Accord Medicine Co., Ltd. 2025 H1 Preliminary Earnings Report](index=1&type=section&id=%E5%9B%BD%E8%8D%AF%E9%9B%86%E5%9B%A2%E4%B8%80%E8%87%B4%E8%8D%AF%E4%B8%9A%E8%82%A1%E4%BB%BD%E6%9C%89%E9%99%90%E5%85%AC%E5%8F%B82025%E5%B9%B4%E5%8D%8A%E5%B9%B4%E5%BA%A6%E4%B8%9A%E7%BB%A9%E5%BF%AB%E6%8A%A5) [Key Financial Data and Indicators](index=1&type=section&id=%E4%B8%80%E3%80%81%E4%B8%BB%E8%A6%81%E4%BC%9A%E8%AE%A1%E6%95%B0%E6%8D%AE%E5%92%8C%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) The company's core financial indicators showed a downward trend in H1 2025, while total assets expanded Key Financial Data for H1 2025 | Key Financial Indicator | Current Period | Prior Year Period | YoY Change (%) | | :--- | :--- | :--- | :--- | | **Total Operating Revenue** | CNY 36.80 billion | CNY 37.79 billion | -2.62% | | **Operating Profit** | CNY 926.50 million | CNY 948.86 million | -2.36% | | **Total Profit** | CNY 918.11 million | CNY 957.97 million | -4.16% | | **Net Profit Attributable to Shareholders** | CNY 665.91 million | CNY 743.49 million | -10.43% | | **Net Profit after Non-recurring Items** | CNY 642.86 million | CNY 711.38 million | -9.63% | | **Basic Earnings Per Share (CNY)** | 1.20 | 1.34 | -10.45% | | **Weighted Average ROE** | 3.70% | 4.19% | Down 0.49 p.p. | | **Total Assets** | CNY 50.43 billion | CNY 47.56 billion | 6.04% | | **Equity Attributable to Shareholders** | CNY 18.14 billion | CNY 17.67 billion | 2.64% | [Explanation of Operating Performance and Financial Condition](index=2&type=section&id=%E4%BA%8C%E3%80%81%E7%BB%8F%E8%90%A5%E4%B8%9A%E7%BB%A9%E5%92%8C%E8%B4%A2%E5%8A%A1%E7%8A%B6%E5%86%B5%E6%83%85%E5%86%B5%E8%AF%B4%E6%98%8E) Overall performance was under pressure due to setbacks in the distribution business, partially offset by significant profit growth in the retail segment [Segment Performance Analysis](index=2&type=section&id=%E5%88%86%E9%83%A8%E4%B8%9A%E7%BB%A9%E5%88%86%E6%9E%90) The performance of the two core business segments diverged, with the distribution segment declining while the retail segment achieved significant profit growth Segment Performance for H1 2025 | Segment | Operating Revenue (CNY billion) | YoY Change | Net Profit (CNY million) | YoY Change | | :--- | :--- | :--- | :--- | :--- | | **Distribution** | 26.78 | -1.09% | 482 | -7.82% | | **Retail** | 10.48 | -6.46% | 17 | +215.81% | - The distribution segment's performance declined due to **industry policy changes**, **intensified market competition**, and **increased provisions for bad debts** from delayed customer payments[5](index=5&type=chunk) - The retail segment's profit surged due to an **optimized procurement system**, **strategic store closures**, and **improved single-store operational quality**, which reduced labor and rental costs[5](index=5&type=chunk) [Other Influencing Factors and Future Outlook](index=2&type=section&id=%E5%85%B6%E4%BB%96%E5%BD%B1%E5%93%8D%E5%9B%A0%E7%B4%A0%E5%8F%8A%E6%9C%AA%E6%9D%A5%E5%B1%95%E6%9C%9B) A decline in investment income from key associate companies negatively impacted overall profit, prompting a future focus on efficiency and digital transformation - Performance decline in key associate companies, affected by industry policies and market dynamics, led to a **reduction in the company's recognized investment income**[6](index=6&type=chunk) - Future strategy will focus on **revenue generation, cost reduction, and efficiency improvement** by accelerating digital transformation and deepening refined management[6](index=6&type=chunk) [Documents for Inspection](index=3&type=section&id=%E4%B8%89%E3%80%81%E5%A4%87%E6%9F%A5%E6%96%87%E4%BB%B6%E7%9B%AE%E5%BD%95) Reference documents include the comparative balance sheet and income statement, signed and sealed by the company's key management personnel - The documents available for inspection are the comparative balance sheet and income statement, signed and sealed by management[8](index=8&type=chunk)

Market Overview - The pharmaceutical commercial sector experienced a slight decline of 0.01% on August 13, with Huaren Health leading the drop [1] - The Shanghai Composite Index closed at 3683.46, up 0.48%, while the Shenzhen Component Index closed at 11551.36, up 1.76% [1] Stock Performance - Key stocks in the pharmaceutical commercial sector showed varied performance, with the following notable movements: - Seli Medical (603716) rose by 6.55% to a closing price of 31.09, with a trading volume of 556,200 shares and a transaction value of 1.671 billion [1] - Guofa Co. (600538) increased by 1.75% to 6.38, with a trading volume of 129,600 shares [1] - Huaren Health (301408) fell by 1.76% to 15.11, with a trading volume of 179,600 shares and a transaction value of 271 million [2] Capital Flow - The pharmaceutical commercial sector saw a net inflow of 33.73 million from institutional investors, while retail investors experienced a net outflow of 42.05 million [2] - Notable capital flows for specific stocks included: - Seli Medical had a net inflow of 10.9 million from institutional investors, while retail investors saw a net outflow of 2.46 million [3] - Yiyang Pharmaceutical (301015) had a net inflow of 6.29 million from institutional investors, but retail investors faced a net outflow of 31.02 million [3]

Core Viewpoint - The company, China National Pharmaceutical Group Corporation (国药一致), has no plans to transition into the molecular diagnostics sector, maintaining its focus on pharmaceutical distribution and retail [2] Company Summary - The main business of the company is pharmaceutical distribution and retail [2] - The company responded to an investor inquiry regarding potential transformation into the molecular diagnostics sector, confirming that there are currently no plans for such a transition [2]

Core Viewpoint - The company has approved a profit distribution plan for the fiscal year 2024, which includes a cash dividend of RMB 3.66 per 10 shares, totaling RMB 203.7 million to be distributed to shareholders [1][5][3]. Group 1: Profit Distribution Plan - The profit distribution plan was approved at the annual shareholders' meeting held on June 10, 2025, based on a total share capital of 556,565,077 shares [1][2]. - The total cash dividend to be distributed amounts to RMB 203,702,818.18, with no stock dividends or capital reserve transfers [1][5]. - The cash dividend will be distributed to all shareholders, with specific tax implications based on the type of shares held [5][6]. Group 2: Dividend Payment Details - The cash dividend of RMB 3.66 per 10 shares is inclusive of tax, with different tax treatments for various types of shareholders [5][6]. - The A-share equity registration date is set for June 24, 2025, and the ex-dividend date is June 25, 2025 [7]. - B-share shareholders will have their last trading day on June 24, 2025, with the same ex-dividend date of June 25, 2025 [7][8]. Group 3: Distribution Method - The cash dividends for A-share shareholders will be directly credited to their accounts through their custodial securities companies on June 25, 2025 [9]. - B-share dividends will be credited on June 27, 2025, with specific instructions for shareholders who may need to handle tax-related issues [9][10]. - The company will bear all legal responsibilities for any discrepancies in the dividend distribution process [9].

国药集团一致药业股份有限公司 2024年年度权益分派实施公告 本公司及董事保证信息披露的内容真实、准确、完整，没有虚假记载、误导性 陈述或重大遗漏。 一、股东大会审议通过利润分配方案情况 1、国药集团一致药业股份有限公司（以下简称"公司"或"本公 司"）2024 年年度利润分配方案已经公司于 2025 年 6 月 10 日召开的 2024 年年度股东大会审议通过，以公司当前总股本 556,565,077 股为基 数，向全体股东每 10 股派发现金股利人民币 3.660000 元（含税），共 计派发现金红利人民币 203,702,818.18 元，不送股，不进行资本公积金 转增股本。 证券代码：000028、200028 证券简称：国药一致、一致B 公告编号：2025-33 若在利润分配方案实施前，公司总股本发生变动的，公司将按照分 配总额不变的原则对分配比例进行调整。 2、自 2024 年年度权益分派方案披露至实施期间，公司股本总额未 发生变化。 3、本次实施的分派方案与股东大会审议通过的分派方案一致。 4、本次实施的分派方案距离股东大会审议通过的时间未超过两个 月。 二、权益分派方案 公司 2024 年年度 ...

General Principles - The rules are established to clarify the responsibilities and decision-making procedures of the board of directors of China National Pharmaceutical Group Corporation [1] - The rules aim to enhance the efficiency of board meetings and ensure scientific decision-making in accordance with relevant laws and regulations [1] Rights and Obligations of Directors - Directors have the right to attend board meetings and exercise voting rights [2] - Directors must act in the best interest of the company and adhere to legal and regulatory obligations [2][3] - Directors are required to treat all shareholders fairly and must not exploit their position for personal gain [2] Responsibilities of Directors - Directors must avoid conflicts of interest and are prohibited from misappropriating company assets or funds [2] - Directors are obligated to maintain confidentiality regarding company secrets even after their term ends [5] - Directors must sign written confirmations for periodic reports to ensure the accuracy and completeness of disclosed information [2] Board Authority - The board is responsible for convening shareholder meetings and executing shareholder resolutions [15] - The board has the authority to decide on major operational plans, investment proposals, and financial distributions [15] - The board must approve external guarantees exceeding certain thresholds based on the company's audited net assets [6] Meeting Procedures - Board meetings can be regular or temporary, with specific notification requirements for each type [12][13] - A quorum of more than half of the directors is required for meetings to be valid [15] - Decisions are made through various voting methods, including show of hands or written ballots [15][16] Committees and Roles - The board may establish specialized committees for strategic, risk control, and audit purposes [12] - The chairman of the board acts as the legal representative and is elected by the board members [17] - The board secretary is responsible for preparing meeting materials and maintaining records [12][17] Disclosure and Compliance - Major resolutions must be reported to the Shenzhen Stock Exchange within two working days [17] - The board must ensure that all meeting records are kept for at least ten years [17] - Any significant internal control deficiencies must be disclosed promptly [10]

Key Points - The annual general meeting of the company will be held on June 10, 2025, with no proposals for addition, rejection, or changes [1] - A total of 270 shareholders and proxies attended the meeting, representing 333,060,816 shares, accounting for 59.84% of the total voting shares [1] - The meeting passed several proposals, including ordinary resolutions for proposals 1, 2, 3, 4, 5, 7, 8, 13, and 14, and special resolutions for proposals 12 and 15 [2][3] - The voting results showed a high approval rate, with over 99% of votes in favor for most proposals, indicating strong shareholder support [2][3][5] - The company appointed two non-independent directors, Mr. Zhang Wei and Mr. Jia Hongbin, to the board, ensuring that the number of management and employee representatives does not exceed half of the total board members [6]

北京市天元（深圳）律师事务所 关于国药集团一致药业股份有限公司 2024 年年度股东大会的法律意见 京天股字（2025）第 392 号 致：国药集团一致药业股份有限公司 国药集团一致药业股份有限公司（以下简称"公司"）2024 年年度股东大会（以 下简称"本次股东大会"）采取现场投票与网络投票相结合的方式，现场会议于 2025 年 6 月 10 日在深圳市福田区八卦四路 15 号一致药业大厦 5 楼会议室召开。北京市 天元（深圳）律师事务所（以下简称"本所"）接受公司聘任，指派本所律师通过现 场方式对本次股东大会进行见证，并根据《中华人民共和国公司法》（以下简称"《公 司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股 东会规则》（以下简称"《股东会规则》"）以及《国药集团一致药业股份有限公司 章程》（以下简称"《公司章程》"）等有关规定，就本次股东大会的召集、召开程 序、出席现场会议人员的资格、召集人资格、会议表决程序及表决结果等事项出具 本法律意见。 本所及经办律师依据《证券法》、《律师事务所从事证券法律业务管理办法》和 《律师事务所证券法律业务执业规则（试行）》等规定及本法律意 ...

2024年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：000028 、200028 证券简称：国药一致、一致B 公告编号：2025-32 国药集团一致药业股份有限公司 一、 重要提示 本公司2024年年度股东大会召开期间无增加、否决或变更提案的 事项。 二、 会议召开和出席情况 1、召开时间： （1）现场会议时间：2025年6月10日（星期二）上午9:30。 （2）网络投票时间： 通过深圳证券交易所交易系统进行投票的时间为2025年6月10日 9:15-9:25，9:30-11:30和13:00-15:00； 通过深圳证券交易所互联网投票系统投票时间为2025年6月10日 9:15-15:00期间的任意时间。 2、现场会议召开地点：深圳市福田区八卦四路15号一致药业大 厦5楼会议室。 3、召开方式：现场投票结合网络投票表决的方式 1 4、召集人：董事会 5、主持人：吴壹建董事长 6、会议的出席情况 （1）出席的总体情况 股东及股东代理人 270 人、代表股份 333,060,816 股、占本公司 有表决权总股份 59.842 ...